Loading clinical trials...
Loading clinical trials...
Assessment of Arformoterol for COPD Using Hyperpolarized 3He MRI
The purpose of this study is to determine efficacy of MR imaging with hyperpolarized helium-3 gas in COPD patients both before and after treatment.
Hyperpolarized Helium Lung imaging has already been tested and proven to be scientifically possible in patients with a number of pulmonary disorders. However there is limited data on the sensitivity of this imaging technique, which would be essential for clinical use. This study is a double blinded study with two cohorts, each cohort being made up of patients with confirmed diagnosis of COPD. One group will receive a placebo while the other will receive treatment. A comparison of the data will resume once twenty patients have been consented and completed the study procedures.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
UMASS Medical School Advanced MRI Center
Worcester, Massachusetts, United States
Start Date
November 1, 2008
Primary Completion Date
April 1, 2011
Completion Date
April 1, 2011
Last Updated
November 1, 2012
16
ACTUAL participants
Hyperpolarized Helium-3
DRUG
Placebo
DRUG
Aformoterol
DRUG
Lead Sponsor
University of Massachusetts, Worcester
NCT07477600
NCT05878769
NCT06717659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions